
The Danish gene analysis company Exiqon and U.S. company Asuragen has signed a partnership deal, which could have a great significance for Exiqon’s possibilities on the U.S. market, according to the Danish company.
Asuragen is a fully integrated molecular diagnostics company focused on oncology and companion diagnostics with special capabilities in the area of miRNA.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app